Shanghai ChemPartner has appointed Lilly Xu, Ph.D. as vice president and the head of DMPK and exploratory toxicology at the company’s headquarters in Shanghai, China.
Previously, Dr. Xu was the head of the Center of Predictive ADMET at Sanofi/Icagen.
"DMPK is important to Chempartner and our biopharmaceutical clients with respect to drug discovery and development to meet unmet medical needs. We needed an experienced leader to maintain the quality of service that keep our clients satisfied and coming back. Dr. Xu's expertise, knowledge, and dedication make her a great fit for the team," said Dr. Wei Tang, president of ChemPartner in the press release.
As the previous senior vice president, biology, biologics, and DMPK, Dr. Tang hired Dr. Xu to lead the DMPK and exploratory toxicology team.